首页> 外文期刊>Pathology International >Malignancies in organ transplant recipients.
【24h】

Malignancies in organ transplant recipients.

机译:器官移植受者的恶性肿瘤。

获取原文
获取原文并翻译 | 示例
           

摘要

The development of cancer in organ transplant recipients is well known; depressed immunosurveillance induced by the use of immunosuppressive agents for prevention of rejection is a causative factor. The types of malignancies in renal transplant patients vary geographically and are influenced by the type of immunosuppressant used. In the present study in Japan, malignancies had developed in 2.6% of renal transplant recipients; the observed number/expected number ratio was 2.78. For the primary sites, the relative risk in Japan was quite different from that in Western countries, with a lower frequency of skin cancer, an absence of Kaposi's sarcoma and higher frequencies of renal and thyroid cancer in Japan. Epstein-Barr virus is an oncogenic virus causing lymphoproliferative disorders in immunocompromised hosts. In renal transplant recipients, who usually receive hemodialysis before transplantation, human T lymphotrophic virus (HTLV)-1 is also oncogenic and causes adult T-cell leukemia/lymphoma. The HTLV-1 in donor blood might be transmitted to transplant recipients via transfusion during hemodialysis. The epidemiology and characteristics of representative malignancies in transplant recipients are described, with a review of pertinent literature.
机译:在器官移植受者中癌症的发展是众所周知的。使用免疫抑制剂预防排斥反应引起的免疫抑制低下是一个致病因素。肾移植患者的恶性肿瘤类型在地理上会有所不同,并受所用免疫抑制剂类型的影响。在日本的本研究中,2.6%的肾移植受者发生了恶性肿瘤。观察数/预期数比为2.78。在主要地区,日本的相对风险与西方国家大不相同,日本的皮肤癌发生率较低,卡波西氏肉瘤不存在,肾癌和甲状腺癌发生率较高。爱泼斯坦-巴尔病毒是一种致癌病毒,可在免疫功能低下的宿主中引起淋巴增生性疾病。在通常在移植前接受血液透析的肾移植受者中,人T淋巴细胞营养病毒(HTLV)-1也具有致癌性,并引起成人T细胞白血病/淋巴瘤。在血液透析期间,供血中的HTLV-1可能会通过输血传播给移植受体。描述了移植受者代表性恶性肿瘤的流行病学和特征,并回顾了相关文献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号